4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors

Cellular Immunology

Volumn 210, Issue 1, 2001, Pages 56-65

  Guinn, Barbara A ^a   Bertram, Edward M ^a   DeBenedette, Mark A ^a   Berinstein, Neil L ^a,b   Watts, Tania H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

4 1BB; CD28; Cytotoxic T cell responses; Tumor immunity

Indexed keywords

4 1BB ANTIGEN; CD137 ANTIGEN; CD137 LIGAND; CD28 ANTIGEN; CD86 ANTIGEN; T LYMPHOCYTE ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CELL LINE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; TUMOR IMMUNITY;

ANIMALIA;

EID: 0035946845     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1006/cimm.2001.1804     Document Type: Article

References (36)

1. CD28/B7 system of T cell costimulation
2. Costimulatory regulation of T cell function
3. T cell costimulatory molecules other than CD28
4. Role of 4-1BB in immune responses
5. OX-40: Life beyond the effector T cell stage
6. Tumor necrosis factor receptor family members in the immune system
7. cDNA sequences of two inducible T-cell genes
8. Inducible T cell antigen 4-1BB: Analysis of expression and function
9. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: A member of an emerging family of cytokines with homology to tumor necrosis factor
10. 4-1BB T cell antigen binds to mature B cells and macrophages, and costimulates anti-μ-primed splenic B cells
11. Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP
12. - T lymphocytes by 4-1BB ligand
13. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28
14. - T cells
15. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses
16. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
17. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand
18. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: Synergy with the CD28 co-stimulatory pathway
19. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies
20. Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses
21. Cutting edge: 4-1BB is a bonafide CD8 T cell survival signal
22. Analysis of 4-1BB ligand-deficient mice and of mice lacking both 4-1BB ligand and CD28 reveals a role for 4-1BB ligand in skin allograft rejection and in the cytotoxic T cell response to influenza virus
23. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses
24. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination
25. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand
26. Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells
27. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death
28. Manipulation of costimulatory signals to enhance antitumor T-cell responses
29. Gene-modified tumor cells as cellular vaccine
30. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
31. Costimulatory wars: The tumor menace
32. 4-1BBL co-operates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long lasting anti-tumor vaccine
33. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: Long-term remission of liver metastases in a mouse model
34. Establishment and characterization of BALB/c lymphoma lines with B cell properties
35. Differential T cell costimulatory requirements in CD28-deficient mice